Fujifilm’s Sayonara To Dr. Reddy’s: Deal To Sell Generics In Japan Shelved
This article was originally published in PharmAsia News
A high-profile joint venture between Fujifilm and Dr. Reddy’s to sell generic drugs in Japan has been terminated only two years after an initial MOU.
You may also be interested in...
After Years Of Partner Search, India's Dr. Reddy's Forms JV With Fujifilm To Tap Japanese Generics Market
MUMBAI - After years of desire to be in the Japanese generics drugs business, Dr. Reddy's Laboratories Ltd. CEO G.V. Prasad reached that milestone in the signing of a memorandum of understanding with Fujifilm Corp. CEO Shigetaka Komori
MUMBAI/TOKYO - Introduction of non-discriminatory or national treatment clauses for Indian generic companies in the latest trade agreement between India and Japan will facilitate wider access for Indian generic firms to the world's second-largest pharma market, but analysts predict headwinds await before companies get a real bang for their buck
Tokyo-based digital imaging maker Fujifilm is venturing further into the pharmaceutical business with the unveiling of the new Fujifilm Pharma, a generic drug joint venture with Mitsubishi and Toho Holdings. The 80-15-5 joint venture aims to start marketing 200 generic drugs starting in April